- Home
- CANF vs LIQT Comparison
CANF vs LIQT Comparison
Compare CANF & LIQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- LIQT
- Stock Information
- Founded
- CANF 1994
- LIQT 2004
- Country
- CANF Israel
- LIQT Denmark
- Employees
- CANF N/A
- LIQT N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- LIQT Industrial Machinery/Components
- Sector
- CANF Health Care
- LIQT Technology
- Exchange
- CANF Nasdaq
- LIQT Nasdaq
- Market Cap
- CANF 14.8M
- LIQT 16.1M
- IPO Year
- CANF N/A
- LIQT N/A
- Fundamental
- Price
- CANF $1.03
- LIQT $1.70
- Analyst Decision
- CANF Strong Buy
- LIQT Strong Buy
- Analyst Count
- CANF 2
- LIQT 2
- Target Price
- CANF $14.00
- LIQT $4.80
- AVG Volume (30 Days)
- CANF 129.3K
- LIQT 15.9K
- Earning Date
- CANF 04-14-2025
- LIQT 08-13-2025
- Dividend Yield
- CANF N/A
- LIQT N/A
- EPS Growth
- CANF N/A
- LIQT N/A
- EPS
- CANF N/A
- LIQT N/A
- Revenue
- CANF $674,000.00
- LIQT $14,986,815.00
- Revenue This Year
- CANF $461.72
- LIQT $36.89
- Revenue Next Year
- CANF N/A
- LIQT $16.33
- P/E Ratio
- CANF N/A
- LIQT N/A
- Revenue Growth
- CANF N/A
- LIQT N/A
- 52 Week Low
- CANF $0.98
- LIQT $1.34
- 52 Week High
- CANF $4.69
- LIQT $3.20
- Technical
- Relative Strength Index (RSI)
- CANF 39.89
- LIQT 52.96
- Support Level
- CANF $1.02
- LIQT $1.58
- Resistance Level
- CANF $1.09
- LIQT $1.64
- Average True Range (ATR)
- CANF 0.04
- LIQT 0.09
- MACD
- CANF -0.00
- LIQT -0.01
- Stochastic Oscillator
- CANF 6.67
- LIQT 44.83
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.